Subscribe To
ATNM / Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
![Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy](https://cdn.snapi.dev/images/v1/e/w/image-1608315467-2140176.jpg)
Content Topics
Actinium
Pharmaceuticals
Trickle
Down
Continues
Maintain
Pharmaceuticals
Continues
Stock
ATNM
ATNM News
![Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy](https://cdn.snapi.dev/images/v1/e/w/image-1608315467-2140176.jpg)
By Seeking Alpha
November 3, 2023
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. Th more_horizontal
![Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar? Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?](https://cdn.snapi.dev/images/v1/k/c/image-1413205702-2066182.jpg)
By Seeking Alpha
September 15, 2023
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?
Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of succes more_horizontal
![Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth](https://cdn.snapi.dev/images/v1/g/q/biotech12-1770549.jpg)
By Investors Business Daily
February 24, 2023
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results. more_horizontal
![Actinium Pharmaceuticals: Prep For February Actinium Pharmaceuticals: Prep For February](https://cdn.snapi.dev/images/v1/q/l/image-1314787309-1701744.jpg)
By Seeking Alpha
January 10, 2023
Actinium Pharmaceuticals: Prep For February
Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators. more_horizontal
![Actinium (ATNM) Up on Commercialization Deal With Immedica Actinium (ATNM) Up on Commercialization Deal With Immedica](https://cdn.snapi.dev/images/v1/t/v/biotech4-1319959.jpg)
By Zacks Investment Research
April 13, 2022
Actinium (ATNM) Up on Commercialization Deal With Immedica
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Euro more_horizontal
![Why Actinium Pharmaceuticals Stock Is Surging Why Actinium Pharmaceuticals Stock Is Surging](https://cdn.snapi.dev/images/v1/8/7/lab-g46d948944-1920-1316889.jpg)
By Benzinga
April 12, 2022
Why Actinium Pharmaceuticals Stock Is Surging
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply ag more_horizontal